眼球玻璃体腔注射抗血管内皮生长因子药物治疗视网膜病变的肾脏毒性  

Renal toxicity of intravitreal injection of anti-vascular endothelial growth factor drugs in the treatment of retinopathy

作　　者：邹雨桐 刘芳[1] ZOU Yutong;LIU Fang(Department of Nephrology,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,P.R.China)

机构地区：[1]四川大学华西医院肾脏内科,成都610041

出　　处：《华西医学》2022年第10期1588-1593,共6页West China Medical Journal

基　　金：国家自然科学基金(81970626,81670662)。

摘　　要：抗血管内皮生长因子(vascular endothelial growth factor,VEGF)药物通过抑制血管生成来治疗恶性肿瘤和糖尿病视网膜病变等眼部疾病,已在临床广泛应用。但近期研究表明眼球玻璃体腔注射抗VEGF药物可能存在显著的全身吸收,导致高血压恶化、蛋白尿加重、新发肾小球疾病、血栓性微血管病等一系列肾脏损害。该文就眼球玻璃体腔内注射抗VEGF药物治疗糖尿病视网膜病变等眼部疾病的肾脏毒性作一综述,旨在为临床医生提供建议。Anti-vascular endothelial growth factor(VEGF) drugs have been widely used in clinic by inhibiting angiogenesis to treat ocular diseases such as malignant tumors and diabetic retinopathy. However, recent studies have shown that intravitreal injection of anti-VEGF drugs may have significant systemic absorption, leading to a series of renal damages such as worsening hypertension, proteinuria, new glomerular disease, and thrombotic microangiopathy. This article reviews the renal toxicity of intravitreal injection of anti-VEGF drugs in the treatment of diabetic retinopathy and other ocular diseases, aiming to provide recommendations for clinicians.

关 键 词：玻璃体腔 抗血管内皮生长因子药物 肾脏毒性 血管内皮生长因子 蛋白尿 血栓性微血管病 

分 类 号：R774.1[医药卫生—眼科]